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S
ince highly active antiretroviral 
treatment (HAART) regimens 
became widely available in 
North America and Europe in 1996, 
the incidence of AIDS-deﬁ  ning 
opportunistic infections and 
malignancies has declined dramatically. 
This decline has been attributed to 
restoration of protective immunity by 
HAART since HAART improves many 
of the deﬁ  cits in T and B cell function 
that are caused by uncontrolled HIV 
infection. Some of these deﬁ  cits 
include diminished antigen-speciﬁ  c 
T cell proliferation and cytokine 
expression, decreased production of 
new naïve T cells by the thymus, and 
abnormally high levels of CD4+ and 
CD8+ T cell and B cell activation [1–3]. 
However, the causal link between the 
reversal or prevention of these T and 
B cell functional abnormalities and 
immune protection against AIDS-
deﬁ  ning opportunistic infections 
and malignancies remains largely 
hypothetical at present.
Protective Immunity against CMV 
Retinitis in AIDS
The best evidence for HAART-induced 
immune reconstitution translating 
into protective immunity is for AIDS-
related cytomegalovirus (CMV) 
retinitis. Before HAART, patients with 
CMV retinitis required lifelong anti-
CMV therapy, and retinitis progressed 
within weeks of discontinuing therapy. 
However, with HAART-related 
increases in absolute CD4+ T cell counts 
to above 100 cells/µl, anti-CMV therapy 
can be discontinued with little risk of 
retinitis progression. 
CMV antigens are well characterized, 
and CMV-speciﬁ  c immune responses 
are robust in healthy CMV-seropositive 
individuals. This means that potential 
correlates of protective immunity 
can be identiﬁ  ed by comparing 
immunoassay results in patients who 
have clear evidence of absent CMV-
protective immunity (i.e., patients 
with AIDS with active CMV retinitis) 
to those in patients who have clear 
evidence of restored CMV-protective 
immunity (i.e., patients with AIDS and 
CMV retinitis who, after HAART, are 
able to discontinue anti-CMV therapy 
without further retinitis reactivation or 
progression). 
For example, we recently identiﬁ  ed 
a pattern of immune function that was 
completely absent in the peripheral 
blood mononuclear cells (PBMC) of 
100% of 24 patients with active CMV 
retinitis but was partially or completely 
present in the PBMC of 85% of 34 
patients with CMV retinitis patients who 
had been clinically immuno-restored by 
HAART [4]. The pattern that we found 
was the presence of CMV antigen-
speciﬁ  c CD4+ T cells that can express 
interleukin-2 and interferon-γ (IFN-γ) 
and of CMV-speciﬁ  c memory CD8+ T 
cells that are not fully differentiated. 
Thus, speciﬁ  c CD4+ and CD8+ T 
cell functional responses to speciﬁ  c 
CMV antigens appear to be good 
candidates for identifying protective 
immunity against AIDS-related CMV 
disease. However, larger, longitudinal, 
observational studies are needed 
to determine the predictive value 
and potential clinical utility of such 
immunoassays in deﬁ  ning CMV-
protective immunity and guiding 
clinical management for patients with 
AIDS with a history of CMV retinitis or 
at risk for developing CMV retinitis.
The Role of EBV in Primary 
CNS Lymphoma
Primary central nervous system 
(PCNS) lymphoma is an AIDS-
deﬁ  ning opportunistic malignancy 
in which Epstein-Barr virus (EBV) 
infection appears to have a critical 
pathogenic role. Like CMV retinitis, 
AIDS-associated PCNS lymphomas 
usually occur in patients with very 
advanced AIDS. The role of EBV in 
the pathogenesis of this disease is 
supported by studies that show the 
presence of EBV-encoded small RNA 
in tissue specimens from virtually all 
cases [5] and the high sensitivity and 
speciﬁ  city of EBV DNA in cerebrospinal 
ﬂ  uid for biopsy- or autopsy-conﬁ  rmed 
primary CNS lymphoma [6]. 
However, the role of EBV viral 
replication and antigen-speciﬁ  c 
immune responses in the pathogenesis 
of primary CNS lymphoma is not as 
clear as that of CMV viral replication 
and antigen-speciﬁ  c immune responses 
in the pathogenesis of CMV retinitis. 
For example, CMV viral load, as 
measured by CMV DNA polymerase 
chain reaction in circulating blood 
or plasma, clearly correlates with 
risk of developing CMV retinitis; 
and circulating CMV DNA becomes 
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undetectable in nearly all patients who 
are immune restored by HAART. In 
contrast, a clear relationship between 
circulating EBV DNA and risk of 
developing AIDS-related lymphoma 
has not been shown, and HAART has 
little effect in reducing circulating 
EBV DNA load in blood [7–9]. 
Analogously, nearly all studies of the 
effect of HAART on CMV-speciﬁ  c T 
cell responses have reported increases 
in these antigen-speciﬁ  c responses after 
HIV replication comes under control. 
However, reports of the effect of 
HAART on EBV-speciﬁ  c T cell function 
are mixed, with increases in certain 
EBV antigen-speciﬁ  c T cell responses 
and decreases in others [7,10].
A New Study of EBV-Speciﬁ  c CD4+ T 
Cell Function and the Development 
of PCNS Lymphoma in AIDS
In a new paper published in PLoS 
Medicine, Olivier Gasser and colleagues 
address the question of whether an 
EBV antigen-speciﬁ  c T cell response 
might be a critical component of 
protective immunity that is lost as 
part of the pathogenesis of AIDS-
related PCNS lymphoma [11]. The 
investigators performed a case-
control study within the longitudinal, 
observational Swiss HIV Cohort Study. 
In six patients diagnosed with primary 
CNS lymphoma, EBV-speciﬁ  c CD4+ T 
cell IFN-γ responses were measured 
in PBMC obtained 0.5–4.7 y before 
lymphoma diagnosis, and these 
responses were compared to the same 
T cell responses in PBMC obtained 
from 16 matched controls (i.e., 
participants who were HIV positive but 
did not develop PCNS lymphoma). 
An ELISPOT assay was used in which 
PBMC were stimulated by a set of EBV 
peptides that, based on the patients’ 
HLA haplotype, were expected to 
stimulate EBV-speciﬁ  c memory CD4+ 
T cell IFN-γ responses, if present. In 
addition, CD8+ T cell–depleted PBMC 
specimens were also stimulated with 
EBV-infected B cell lysates in order to 
detect an EBV-speciﬁ  c CD4+ T cell IFN-γ 
response. One of the six cases versus 
13 of the 16 matched controls had a 
detectable EBV-speciﬁ  c CD4+ T cell 
IFN-γ response. Of particular interest, 
three of the six cases developed PCNS 
lymphoma after being immune restored 
by HAART with absolute CD4+ T cell 
counts consistently above 200 cells/µl.
The strengths of this paper are 
the case-control method applied to 
a well-designed, prospective study 
in which samples were tested from 
time points before disease diagnosis. 
The limitations of the study are the 
small sample size (and thus limited 
generalizabililty), the absence of any 
EBV-speciﬁ  c CD8+ T cell functional 
measurements (which may be 
important in protective immunity), 
and the absence of any measurements 
of T or B cell activation (which 
are reported to have a role in the 
immunopathogenesis of AIDS-related 
non-Hodgkin’s lymphoma). Also, no 
additional studies were done to provide 
insight into the mechanism by which 
the three immune-restored patients 
developed primary CNS lymphoma. 
Perhaps these three patients failed 
to reconstitute a sufﬁ  ciently diverse 
T cell receptor repertoire to respond 
to critical EBV epitopes, or perhaps 
persistent T cell activation and 
apoptosis (programmed cell death) led 
to the loss of critical EBV-speciﬁ  c CD4+ 
T cell responses?
Conclusion
Although the results of this paper 
are intriguing, they do not have 
implications for clinical practice at 
this time, but should stimulate new 
studies designed to tease out the 
critical components of EBV-speciﬁ  c 
protective immunity. If we can ﬁ  nd 
pathogen-speciﬁ  c immune responses 
that have predictive value for deﬁ  ning 
clinical protective immunity, these 
responses could potentially be used 
in clinical practice. Such responses 
could become part of new clinical 
management strategies for determining 
(1) how best to clinically monitor 
HIV-infected patients with a history of 
speciﬁ  c opportunistic infections and 
malignancies or at particular risk for 
developing these complications, and 
(2) when pathogen-speciﬁ  c therapy for 
such complications should be initiated 
and discontinued.  
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